Payment overview · 2025
General Payments
$40,768.14
140 reported records · 19 companies
Healthcare provider profile · identity verified
Sergey Ayzenberg, M.D
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BROOKLYN, NY · NPI 1306031125
Verified facts
What the public records show
CMS Open Payments records show Sergey Ayzenberg, M.D received $40,768.14 in general payments during 2025 across 140 reported records.
Medtronic, Inc. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$12,110.06 | 29.7% | 22 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $12,108.24 | 29.7% | 26 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $11,763.47 | 28.9% | 29 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $1,296.06 | 3.2% | 13 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,035.26 | 2.5% | 5 | 2025 |
| ASAHI INTECC USA, INC. | Unresolved — no canonical attribution shown | $664.85 | 1.6% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $448.72 | 1.1% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $193.40 | 0.5% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $176.16 | 0.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $175.00 | 0.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $165.64 | 0.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.42 | 0.3% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.71 | 0.3% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $116.57 | 0.3% | 5 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $105.71 | 0.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.93 | 0.1% | 3 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $41.85 | 0.1% | 3 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $39.91 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $22.18 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,583.25 | 10 |
| Consulting Fee | $9,350.00 | 8 |
| Food and Beverage | $6,782.82 | 108 |
| Travel and Lodging | $3,052.07 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $12,110.06 | 22 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $11,777.60 | 23 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $11,763.47 | 29 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $1,169.00 | 9 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,035.26 | 5 | 2025 |
Source payment records
|
|||||
| Asahi Peripheral Vascular Wires Normalized: asahi peripheral vascular wires |
Device | ASAHI INTECC USA, INC. | $664.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $448.72 | 6 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $193.40 | 2 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $176.16 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $175.00 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $138.42 | 7 | 2025 |
Source payment records
|
|||||
| Coronary Undivided Normalized: coronary undivided |
Device | Philips North America LLC | $127.06 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $116.57 | 5 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $105.71 | 3 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $99.31 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $39.91 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $33.78 | 2 | 2025 |
Source payment records
|
|||||
| ZENITH ALPHA Normalized: zenith alpha |
Device | Cook Medical LLC | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $10.66 | 1 | 2025 |
Source payment records
|
|||||
| ADVANCE Normalized: advance |
Device | Cook Medical LLC | $8.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 396 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 110 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 78 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
110 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 78 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 455 | 113 |
| Clopidogrel | Clopidogrel Bisulfate | 422 | 89 |
| Eliquis | Apixaban | 396 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 376 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 357 | 97 |
| Repatha Sureclick | Evolocumab | 327 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 278 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 233 | 57 |
| Carvedilol | Carvedilol | 222 | 54 |
| Ranolazine Er | Ranolazine | 179 | 34 |
| Furosemide | Furosemide | 172 | 49 |
| Losartan Potassium | Losartan Potassium | 169 | 42 |
| Nifedipine Er | Nifedipine | 166 | 31 |
| Ezetimibe | Ezetimibe | 147 | 29 |
| Brilinta | Ticagrelor | 144 | 26 |
| Valsartan | Valsartan | 115 | 28 |
| Entresto | Sacubitril/Valsartan | 110 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 110 | 22 |
| Lisinopril | Lisinopril | 104 | 21 |
| Enalapril Maleate | Enalapril Maleate | 102 | 21 |
| Spironolactone | Spironolactone | 99 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 88 | 22 |
| Prasugrel Hcl | Prasugrel Hcl | 80 | 16 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 79 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 77 | 14 |
| Omeprazole | Omeprazole | 75 | suppressed |
| Bumetanide | Bumetanide | 74 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 74 | 14 |
| Vascepa | Icosapent Ethyl | 69 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 53 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 53 | 12 |
| Clonidine Hcl | Clonidine Hcl | 46 | 17 |
| Nitroglycerin | Nitroglycerin | 37 | 20 |
| Nitroglycerin Patch | Nitroglycerin | 36 | suppressed |
| Praluent Pen | Alirocumab | 35 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Multaq | Dronedarone Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Nifedipine | Nifedipine | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Toprol Xl | Metoprolol Succinate | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $40,768.14 · 140 records | Medtronic, Inc. | ADVANCE, AMVUTTRA, ARTIX MT, Asahi Peripheral Vascular Wires, Attruby, CAMZYOS, Coronary Other, Coronary Undivided, ELIQUIS, ENTRESTO, FARAPULSE, Indigo System, Kerendia, LEQVIO, LifeVest, NAVITOR, REPATHA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VERQUVO, VYNDAQEL, ZENITH ALPHA, ZILVER PTX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error